BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 34211801)

  • 1. Increased frequency of TIGIT
    Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
    Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
    Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
    Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.
    Marius W; Leticia OF; Friedrich KN; Stephan M; Louisa H; Tabea S; Elisa S; Pauline W; Yi D; Qi M; Barbara S; Carsten B; Walter F; Jasmin W; Franziska B
    Oncoimmunology; 2024; 13(1):2346359. PubMed ID: 38737794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition.
    Wildner NH; Walker A; Brauneck F; Ditt V; Peine S; Huber S; Haag F; Beisel C; Timm J; Schulze Zur Wiesch J
    Front Immunol; 2022; 13():886646. PubMed ID: 35734162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT blockade repolarizes AML-associated TIGIT
    Brauneck F; Fischer B; Witt M; Muschhammer J; Oelrich J; da Costa Avelar PH; Tsoka S; Bullinger L; Seubert E; Smit DJ; Bokemeyer C; Ackermann C; Wellbrock J; Haag F; Fiedler W
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
    Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
    Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of CD73 associates with T cell exhaustion in AML patients.
    Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
    J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML.
    Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia.
    Huang Y; Zheng H; Zhu Y; Hong Y; Zha J; Lin Z; Li Z; Wang C; Fang Z; Yu X; Liu L; Xu B
    Front Immunol; 2023; 14():1139517. PubMed ID: 36960073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
    Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
    J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and TIGIT Are Highly Co-Expressed on CD8
    Xu L; Liu L; Yao D; Zeng X; Zhang Y; Lai J; Zhong J; Zha X; Zheng R; Lu Y; Li M; Jin Z; Hebbar Subramanyam S; Chen S; Huang X; Li Y
    Front Oncol; 2021; 11():686156. PubMed ID: 34490086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher TIGIT+ γδ T
    Hou Q; Wang P; Kong X; Chen J; Yao C; Luo X; Li Y; Jin Z; Wu X
    Front Immunol; 2024; 15():1321126. PubMed ID: 38711501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
    Kong Y; Zhu L; Schell TD; Zhang J; Claxton DF; Ehmann WC; Rybka WB; George MR; Zeng H; Zheng H
    Clin Cancer Res; 2016 Jun; 22(12):3057-66. PubMed ID: 26763253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8
    Yan L; Yang JR; Wang HQ; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(27):2095-2099. PubMed ID: 37455127
    [No Abstract]   [Full Text] [Related]  

  • 17. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT
    Zeng X; Yao D; Liu L; Zhang Y; Lai J; Zhong J; Zha X; Lu Y; Jin Z; Chen S; Li Y; Xu L
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):456-464. PubMed ID: 34811925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer.
    Weimer P; Wellbrock J; Sturmheit T; Oliveira-Ferrer L; Ding Y; Menzel S; Witt M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Brauneck F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate acid promotes PD-1
    Zhang Y; Huang Y; Hong Y; Lin Z; Zha J; Zhu Y; Li Z; Wang C; Fang Z; Zhou Z; Peng Y; Yu X; Liu L; Xu B
    Int Immunopharmacol; 2024 Mar; 130():111765. PubMed ID: 38447414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.